Ranke M B, Lindberg A
Paediatric Endocrinology Section, Eberhard-Karls-Universität, Tübingen, Germany.
Acta Paediatr Suppl. 1996 Oct;417:18-26. doi: 10.1111/j.1651-2227.1996.tb14288.x.
The response to growth hormone (GH) therapy was studied in children born small for gestational age (SGA; n = 593) and in those with Silver-Russell syndrome (SRS; n = 127) using data from KIGS (Kabi International Growth Study). For the SGA patients, median birth weight was -2.6 SD scores (SDS), treatment was started at a median age of 9.2 years, at a time when median height was -2.8 SDS while median target height was -1.4 SDS. For the SRS patients, median birth weight was -3.1 SDS, treatment was started at a median age of 7.0 years, at a time when median height was -3.4 SDS with a median target height of -0.1 SDS. GH treatment increased height SDS in both SGA children and patients with SRS; in 16 SGA patients treated to (near) final height with GH (median dose, 0.7 IU/kg/week), height minus target height SDS was -2.0 at the start of treatment and -1.0 at final height. In conclusion, the results obtained in KIGS indicate that GH treatment of short children born SGA is effective in increasing final height above the predicted height and in achieving the target height.
利用KIGS（卡比国际生长研究）的数据，对小于胎龄儿（SGA；n = 593）和患有Silver-Russell综合征（SRS；n = 127）的儿童进行了生长激素（GH）治疗反应的研究。对于SGA患者，出生体重中位数为-2.6标准差评分（SDS），治疗开始时的中位年龄为9.2岁，此时中位身高为-2.8 SDS，而中位靶身高为-1.4 SDS。对于SRS患者，出生体重中位数为-3.1 SDS，治疗开始时的中位年龄为7.0岁，此时中位身高为-3.4 SDS，中位靶身高为-0.1 SDS。GH治疗使SGA儿童和SRS患者的身高SDS均增加；在16例接受GH治疗至（接近）最终身高的SGA患者中（中位剂量，0.7 IU/kg/周），治疗开始时身高减去靶身高的SDS为-2.0，最终身高时为-1.0。总之，KIGS获得的结果表明，对出生时为SGA的矮身材儿童进行GH治疗可有效提高最终身高，使其高于预测身高并达到靶身高。
